Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
Syndax Pharmaceuticals, Inc. – $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 – –…
Immune environment found to influence success of leukemia immunotherapy
A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics made a pivotal discovery in the field of cancer…